The Meeting of the Board of Directors of the Company was held on February 12, 2026, which considered and took on record the Unaudited Standalone and Consolidated Financial Results of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics' board on February 12, 2026 approved unaudited results for Q3 and nine months ended December 31, 2025. On a standalone basis, revenue from operations fell about 21% to Rs. 1,924.23 lakhs for 9M FY26 (from Rs. 2,432.31 lakhs a year ago), though the company narrowed its loss to Rs. 168.48 lakhs from Rs. 362.84 lakhs, and posted a Q3 standalone profit of Rs. 98.08 lakhs versus a Rs. 16.74 lakh loss last year. On a consolidated basis, revenue jumped roughly 53% to Rs. 11,927.08 lakhs for 9M FY26 and the group swung to a Rs. 190.77 lakh profit from a Rs. 295.04 lakh loss. The board also flagged a Labour Commissioner order directing Rs. 8.82 crore recovery, which the company will challenge in the High Court, and confirmed receipt of remaining Rs. 3.75 crore plus Rs. 62.74 lakh dividend from the voluntary liquidation of subsidiary GSV Ophthalmics.
Consolidated results show a clear turnaround with strong revenue growth and a return to profit, which is positive for shareholders. However, standalone performance still lags and the Rs. 8.82 crore Labour Court order remains a pending overhang if the High Court challenge fails.